Datavant vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
Datavant is the largest health data ecosystem connecting healthcare organizations through privacy-preserving tokenization that enables real-world data linkage across systems.
About
Datavant is a health data company founded in 2017 that has built the largest real-world health data ecosystem in the United States through its privacy-preserving data tokenization technology. The company's platform enables healthcare organizations including hospitals, insurers, pharmaceutical companies, and research institutions to link patient records across databases without sharing identifying information, using consistent de-identified tokens that allow data to be joined securely. Datavant raised over $600M and expanded significantly through its merger with Ciox Health, combining Datavant's tokenization technology with Ciox's medical record retrieval operations. The company serves life sciences companies that need real-world evidence from claims, EHR, and specialty data sources, payers managing population health programs, and health systems that want to generate revenue from their patient data while maintaining privacy compliance. Datavant's network effect grows as more organizations adopt the tokenization standard, making the ecosystem more valuable for every participant. The platform has become critical infrastructure for real-world evidence generation in pharmaceutical development and health economics research.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.